Amphetamine Addiction Clinical Trial
Cannabidiol as a New Intervention for Amphetamine Dependence: A Proof-of-concept Study
|Source||Centre hospitalier de l'Université de Montréal (CHUM)|
|Status||Not yet recruiting|
|Start date||October 2016|
Addiction to amphetamine is characterized by alternating phases of intoxication and short
abstinence, followed by recurrent drug-craving episodes which result in distress and
relapse. Addiction involves a number of neurotransmission systems, including the
endocannabinoid system (ECBS). Cannabidiol (CBD), the second most abundant component of
cannabis, is known for its broad spectrum of physiological, anxiolytic and neuroprotective
properties. It has been shown to have multiple therapeutic properties for treating anxiety,
schizophrenia and interestingly CBD has been shown to be potentially helpful in treating
addiction, due to its effects on various neuronal circuits involved in this disorder.
Our overall hypothesis is that CBD is an interesting pharmacological contender to decrease amphetamine craving and treat amphetamine addiction.
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
|Not yet recruiting||